UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates

Gene therapy, 2016-10, Vol.23 (10), p.753-759

2016

Volltextzugriff (PDF)

883 VACCINATION AGAINST HEPATITIS C VIRUS WITH A RECOMBINANT FUSION PROTEIN CONTAINING THE EXTRA DOMAIN A FROM FIBRONECTIN AND THE HEPATITIS C VIRUS NS3 PROTEIN

Journal of hepatology, 2009, Vol.50, p.S321-S321

2009

Volltextzugriff (PDF)

1163 EDA-STREPTAVIDIN FUSION PROTEIN CONJUGATED TO BIOTINYLATED HCV-NS3 PROTEIN INDUCES STRONG T CELL IMMUNE RESPONSES AGAINST NS3

Journal of hepatology, 2013-04, Vol.58, p.S473-S473

2013

Volltextzugriff (PDF)

Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus

Vaccine, 2002-12, Vol.21 (3), p.202-210

2002

Volltextzugriff (PDF)

SCHU-20: E-Cadherin Predictive Value for Recurrence of Bladder Noninvasive Tumors (Ta-T1)

Urology (Ridgewood, N.J.), 2008, Vol.72 (5), p.S9-S9

2008

Volltextzugriff (PDF)

SCHU-19: Results of a Conservative Approach in Pyeloureteral Tumors

Urology (Ridgewood, N.J.), 2008, Vol.72 (5), p.S8-S9

2008

Volltextzugriff (PDF)

The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative

International journal of molecular sciences, 2016-02, Vol.17 (3), p.313-313

2016

Volltextzugriff (PDF)

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination

The Journal of immunology (1950), 2003-12, Vol.171 (11), p.5931-5939

2003

Volltextzugriff (PDF)

[472] INDUCTION OF POTENT AND LONG LASTING CD4 AND CDS T-CELL RESPONSES AGAINST HEPATITIS C VIRUS BY IMMUNIZATION WITH VIRAL ANTIGENS PLUS POLY(I:C) AND ANTI-CD40

Journal of hepatology, 2007, Vol.46, p.S179-S179

2007

Volltextzugriff (PDF)

Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses

Journal of Virology, 2003-10, Vol.77 (20), p.10862-10871

2003

Volltextzugriff (PDF)

Predictive score of success adapted to our environment to improve results of extracorporeal lithotripsy

Archivos españoles de urología, 2016-09, Vol.69 (7), p.398

2016

Volltextzugriff (PDF)

Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus

Vaccine, 2005-05, Vol.23 (27), p.3493-3499

2005

Volltextzugriff (PDF)

Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40

Antiviral research, 2007-04, Vol.74 (1), p.25-35

2007

Volltextzugriff (PDF)

A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage

Hepatology (Baltimore, Md.), 2003-02, Vol.37 (2), p.461-470

2003

Volltextzugriff (PDF)

387 Protection against infection with an HCV-recombinant vaccinia virus by vaccination with an adenoviral vector enconding hepatitis C virus (HCV) NS4A protein

Journal of hepatology, 2004, Vol.40, p.115-116

2004

Volltextzugriff (PDF)

Expression of core and E1 proteins from hepatitis C virus in dendritic cells impairs T cell induction in vivo

Journal of hepatology, 2003-04, Vol.38, p.15-15

2003

Volltextzugriff (PDF)

CD4 super(+)/CD25 super(+) Regulatory Cells Inhibit Activation of Tumor-Primed CD4 super(+) T Cells with IFN- gamma -Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

The Journal of immunology (1950), 2003-01, Vol.171 (11), p.5931-5939

2003

Volltextzugriff (PDF)

A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine induced liver damage: A possible mechanism for viral persistence

Journal of hepatology, 2003-04, Vol.38, p.9-9

2003

Volltextzugriff (PDF)

Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus

Journal of hepatology, 2003-04, Vol.38, p.109-109

2003

Volltextzugriff (PDF)

El potencial de la inmunomodulación con anticuerpos monoclonales anti-CD137 (4-1BB) para terapia de enfermedades malignas e infecciones virales crónicas

Anales del sistema sanitario de Navarra, 2006-04, Vol.29 (1), p.77-96

2006

Volltextzugriff (PDF)

HLA-A0201 specific immunogenicity of modified vaccinia virus Ankara (MVA) produced hepatitis C virus antigens -: Advantage of heterologous prime boost vaccination

HEPATOLOGY, 2004, Vol.40 (4), p.733A

2004

Volltextzugriff (PDF)

The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases

Anales del sistema sanitario de Navarra, 2006-01, Vol.29 (1), p.77-96

2006

Volltextzugriff (PDF)

Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells

Nature communications, 2018-07, Vol.9 (1), p.2992-13, Article 2992

2018

Volltextzugriff (PDF)

Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens

Journal for immunotherapy of cancer, 2020-06, Vol.8 (1), p.e000704

2020

Volltextzugriff (PDF)

Characteristics and Surgical Outcomes in Very Elderly Patients (≥75 years) with Renal Cell Carcinoma: Data from the Latin American Renal Cancer Group

Revista de investigacion clinica, 2020-09, Vol.72 (5), p.308-315

2020

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(25)
Tagungsberichte
(1)

Sprache

Englisch
(23)
Spanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(12)
Life Sciences & Biomedicine
(11)
Animals
(10)
Mice
(9)
Humans
(8)
Mice, Inbred Balb C
(6)
Female
(5)
Immunization
(5)
Immunology
(5)
Virology
(5)
Biological And Medical Sciences
(4)
Cd4-Positive T-Lymphocytes - Immunology
(4)
Hepacivirus - Immunology
(4)
Hepatitis C Virus
(4)
Vaccination
(4)
Vaccines
(4)
Adenoviridae - Genetics
(3)
Cancer Vaccines - Immunology
(3)
Cd8-Positive T-Lymphocytes - Immunology
(3)
Gastroenterology And Hepatology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates

883 VACCINATION AGAINST HEPATITIS C VIRUS WITH A RECOMBINANT FUSION PROTEIN CONTAINING THE EXTRA DOMAIN A FROM FIBRONECTIN AND THE HEPATITIS C VIRUS NS3 PROTEIN

1163 EDA-STREPTAVIDIN FUSION PROTEIN CONJUGATED TO BIOTINYLATED HCV-NS3 PROTEIN INDUCES STRONG T CELL IMMUNE RESPONSES AGAINST NS3

Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus

SCHU-20: E-Cadherin Predictive Value for Recurrence of Bladder Noninvasive Tumors (Ta-T1)

SCHU-19: Results of a Conservative Approach in Pyeloureteral Tumors

The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination

[472] INDUCTION OF POTENT AND LONG LASTING CD4 AND CDS T-CELL RESPONSES AGAINST HEPATITIS C VIRUS BY IMMUNIZATION WITH VIRAL ANTIGENS PLUS POLY(I:C) AND ANTI-CD40

Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses

Predictive score of success adapted to our environment to improve results of extracorporeal lithotripsy

Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus

Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40

A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage

387 Protection against infection with an HCV-recombinant vaccinia virus by vaccination with an adenoviral vector enconding hepatitis C virus (HCV) NS4A protein

Expression of core and E1 proteins from hepatitis C virus in dendritic cells impairs T cell induction in vivo

CD4 super(+)/CD25 super(+) Regulatory Cells Inhibit Activation of Tumor-Primed CD4 super(+) T Cells with IFN- gamma -Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine induced liver damage: A possible mechanism for viral persistence

Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus

El potencial de la inmunomodulación con anticuerpos monoclonales anti-CD137 (4-1BB) para terapia de enfermedades malignas e infecciones virales crónicas

HLA-A0201 specific immunogenicity of modified vaccinia virus Ankara (MVA) produced hepatitis C virus antigens -: Advantage of heterologous prime boost vaccination

The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases

Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells

Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens

Characteristics and Surgical Outcomes in Very Elderly Patients (≥75 years) with Renal Cell Carcinoma: Data from the Latin American Renal Cancer Group

Suchergebnisse filtern